Get started

Financials · ACIU

AC Immune SA (ACIU) financials

For fiscal 2025 (ended Dec 31, 2025), AC Immune SA reported CHF 3.57M of revenue and -CHF 70.45M of net income. Figures are in CHF, the currency of its SEC filings.

Revenue, FY2025
CHF 3.57M
Revenue growth, YoY
-86.9%
Net income, FY2025
-CHF 70.45M
Net margin
-1971.6%
Free cash flow, FY2025
-CHF 70.16M
EPS, diluted, FY2025
-CHF 0.70
Cash
CHF 26.80M
Annual revenueCHF 3.57M
FY2016FY2025
Annual net income-CHF 70.45M
FY2016FY2025
Annual free cash flow-CHF 70.16M
FY2016FY2025

ACIU revenue and earnings growth

ACIU revenueFY2025CHF 3.57M

FY YoY
-86.9%
5Y CAGR
-25.4%
10Y CAGR
-21.3%

ACIU revenue was CHF 3.57M for fiscal 2025 (ended Dec 31, 2025), down 86.9% from fiscal 2024. Compound annual growth was -25.4% over 5 years and -21.3% over 10 years. It rose in 2 of the last 3 fiscal years.

ACIU net incomeFY2025-CHF 70.45M

ACIU net income was -CHF 70.45M for fiscal 2025 (ended Dec 31, 2025), compared with -CHF 50.92M in fiscal 2024.

ACIU EPSFY2025-CHF 0.70

ACIU diluted EPS was -CHF 0.70 for fiscal 2025 (ended Dec 31, 2025), compared with -CHF 0.51 in fiscal 2024.

ACIU free cash flowFY2025-CHF 70.16M

ACIU free cash flow was -CHF 70.16M for fiscal 2025 (ended Dec 31, 2025), compared with CHF 65.27M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
RevenueCHF 3.57MCHF 27.31MCHF 14.80MCHF 3.94MCHF 0CHF 15.43MCHF 110.46MCHF 6.91MCHF 20.25MCHF 23.21M
Research and developmentCHF 56.44MCHF 62.57MCHF 54.61MCHF 60.34MCHF 62.28MCHF 59.49MCHF 50.43MCHF 44.28MCHF 32.66MCHF 25.77M
Selling, general and adminCHF 16.09MCHF 17.26MCHF 15.30MCHF 15.79MCHF 17.91MCHF 18.56MCHF 16.06MCHF 12.47MCHF 10.13MCHF 7.90M
Operating income-CHF 69.32M-CHF 52.38M-CHF 53.62M-CHF 70.85M-CHF 79.01M-CHF 61.26MCHF 44.54M-CHF 49.55M-CHF 22.54M-CHF 10.46M
Interest expenseCHF 191.0KCHF 133.0KCHF 176.0KCHF 355.0KCHF 581.0KCHF 184.0KCHF 1.93MCHF 334.0KCHF 147.0KCHF 7.0K
Pre-tax income-CHF 70.45M-CHF 50.91M-CHF 54.22M-CHF 70.74M-CHF 72.99M-CHF 61.92MCHF 45.44M-CHF 50.95M-CHF 26.41M-CHF 7.10M
Income taxCHF 0CHF 3.0KCHF 10.0KCHF 13.0KCHF 3.0KCHF 0CHF 0CHF 0CHF 0CHF 0
Net income-CHF 70.45M-CHF 50.92M-CHF 54.23M-CHF 70.75M-CHF 73.00M-CHF 61.92MCHF 45.44M-CHF 50.95M-CHF 26.41M-CHF 7.10M
EPS, basic-CHF 0.70-CHF 0.51-CHF 0.64-CHF 0.85-CHF 0.97-CHF 0.86CHF 0.64-CHF 0.82-CHF 0.46-CHF 0.14
EPS, diluted-CHF 0.70-CHF 0.51-CHF 0.64-CHF 0.85-CHF 0.97-CHF 0.86CHF 0.64-CHF 0.82-CHF 0.46-CHF 0.14
Diluted shares100.8M99.7M84.7M83.6M75.0M71.9M71.1M61.8M57.1M50.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalentsCHF 26.80MCHF 36.27MCHF 78.49MCHF 31.59MCHF 82.22MCHF 160.89MCHF 193.59MCHF 156.46MCHF 124.38MCHF 152.21M
Current assetsCHF 96.72MCHF 171.99MCHF 125.15MCHF 128.09MCHF 202.63MCHF 231.77MCHF 292.77MCHF 192.93MCHF 129.53MCHF 154.89M
Total assetsCHF 154.25MCHF 230.91MCHF 182.81MCHF 185.94MCHF 261.44MCHF 238.74MCHF 299.25MCHF 196.56MCHF 132.01MCHF 156.10M
Current liabilitiesCHF 94.69MCHF 100.84MCHF 13.58MCHF 11.48MCHF 20.03MCHF 14.02MCHF 17.51MCHF 13.08MCHF 9.75MCHF 9.92M
Total liabilitiesCHF 109.37MCHF 118.64MCHF 22.17MCHF 16.95MCHF 29.46MCHF 23.26MCHF 26.81MCHF 18.93MCHF 15.17MCHF 13.72M
Shareholders' equityCHF 44.88MCHF 112.27MCHF 160.64MCHF 168.99MCHF 231.98MCHF 215.48MCHF 272.44MCHF 177.62MCHF 116.84MCHF 142.38M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-CHF 69.26MCHF 65.84M-CHF 60.41M-CHF 73.57M-CHF 65.69M-CHF 59.52MCHF 55.22M-CHF 44.08M-CHF 22.09M-CHF 5.65M
Capital expendituresCHF 900.0KCHF 576.0KCHF 801.0KCHF 1.24MCHF 2.63MCHF 1.71MCHF 1.89MCHF 1.86MCHF 1.80MCHF 899.0K
Free cash flow-CHF 70.16MCHF 65.27M-CHF 61.21M-CHF 74.81M-CHF 68.32M-CHF 61.22MCHF 53.34M-CHF 45.94M-CHF 23.90M-CHF 6.54M
Investing cash flowCHF 63.54M-CHF 105.29MCHF 65.64MCHF 23.76M-CHF 53.66MCHF 28.33M-CHF 66.89M-CHF 32.04M-CHF 1.84M-CHF 899.0K
Financing cash flow-CHF 1.02M-CHF 1.12MCHF 43.25M-CHF 1.35MCHF 40.75M-CHF 803.0KCHF 49.62MCHF 109.38MCHF 271.0KCHF 78.79M
Share repurchases---CHF 0CHF 0CHF 100.0KCHF 0CHF 0--
Stock-based compensationCHF 4.40MCHF 5.47MCHF 4.37MCHF 3.33MCHF 4.13MCHF 4.09MCHF 2.83MCHF 2.52MCHF 1.58MCHF 1.32M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-86.9%84.5%276.1%--100.0%-86.0%1498.0%-65.9%-12.7%-40.6%
Operating margin-1940.1%-191.8%-362.3%-1800.4%--397.0%40.3%-716.9%-111.3%-45.0%
Net margin-1971.6%-186.4%-366.4%-1798.0%--401.3%41.1%-737.1%-130.4%-30.6%
Free cash flow margin-1963.7%239.0%-413.5%-1901.1%--396.8%48.3%-664.6%-118.0%-28.2%
Return on equity-157.0%-45.4%-33.8%-41.9%-31.5%-28.7%16.7%-28.7%-22.6%-5.0%
Return on assets-45.7%-22.0%-29.7%-38.1%-27.9%-25.9%15.2%-25.9%-20.0%-4.5%
Current ratio1.021.719.2211.1610.1216.5316.7214.7513.2815.61

Source: XBRL data AC Immune SA files with the SEC, latest filing dated Mar 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ACIU peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ACIUCHF 3.57M-86.9%-CHF 70.45M-1971.6%$248.3M
PRTA$52.73M+347.4%-$23.96M-45.4%$450.9M
ALEC$173.47M+151.2%$41.41M23.9%$366.2M
ANVS$0--$49.52M-$38.6M
ABOS---$103.96M-$17.6M

ACIU FAQ

8 questions
  • What is ACIU revenue?
    AC Immune SA (ACIU) reported CHF 3.57M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 86.9% from the year before.
  • Is ACIU profitable?
    No. AC Immune SA reported a net loss of CHF 70.45M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does ACIU have?
    AC Immune SA reported CHF 26.80M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ACIU revenue growing?
    AC Immune SA's revenue changed -86.9% in fiscal 2025, to CHF 3.57M. Its compound annual growth rate was -25.4% over 5 years and -21.3% over 10 years.
  • What is ACIU free cash flow?
    AC Immune SA generated -CHF 70.16M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -CHF 69.26M less capital expenditures.
  • What is ACIU earnings per share?
    Diluted earnings per share were -CHF 0.70 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did ACIU last report financial results?
    The latest statements here come from AC Immune SA's 20-F filed on Mar 13, 2026, covering the period ended Dec 31, 2025.
  • Where does this ACIU financial data come from?
    Quantisnow builds these statements from the structured XBRL data AC Immune SA files with the SEC. It is provided for information only and is not investment advice.